When: Zola-cel safety update clears or Q3 2026 earnings confirms trajectory

Then: Deploy third tranche of ~0.5–1.0% of equity book

WAIT FOR PULLBACK OR REDUCE POSITION SIZE

• Q2 2025 EPS of $0.64 was a depressed comparison quarter, making the 153% year-over-year increase misleading rather than 'escape velocity'
• Forward EPS of $6.56 is 'potentially heroic' and even a $0.10 miss collapses the multiple expansion thesis at 11x earnings
• Eliquis faces loss of exclusivity in 2026-2028 window with roughly 30% of revenue at risk; Cobenfy and Reblozyl (5.7% revenue growth in one quarter) insufficient to offset
• Zola-cel pause represents platform/reputational risk across entire cell therapy franchise including Breyanzi and Abecma, not just a single asset
• MACD bearish cross with RSI at 64 and percent-B at 0.83 indicates buying at most stretched short-term setup in over a month
• Volume confirmation: 6.22 million shares on latest leg versus 32.97 million on early August breakout signals weak push, not accumulation
• Stop loss at $62.61 (50 SMA) risks 14% drawdown to 200 SMA at $57.20 on gap-down catalyst rather than stated 5.5% downside
• 3.7% dividend yield provides less defensive value in hawkish Fed environment as income attractiveness compresses vs short-term rates
• Beta of 0.225 protects against market beta but not against company-specific pipeline risk (zola-cel, Eliquis LOE)
• Preferred entry: pullback to $64.50-$65.50 zone where 10 EMA coiled and MACD reset closer to neutral
• Alternative: cut first tranche to 0.5% of book instead of 1-1.5% to maintain asymmetric structure with less capital at risk
• Third option: sell cash-secured puts at $62-$63 strike for October/November expiration to collect 1.5-2% premium while waiting

→ vs aggressive: Base quarter distortion: Q2 2025 EPS of $0.64 was artificially depressed from integration noise (Karuna and RayzeBio deals), not a normal operating quarter, making the 153% recovery meaningless as a standalone metric

→ vs aggressive: Oxford Biomedica dropping 15% proves supply chain impact, not that the news is priced in for BMY; headline risk for Bristol Myers hasn't fully played out pending detailed safety update

→ vs aggressive: MACD terminology reversed: higher highs with declining momentum is bearish divergence (warns of trend exhaustion), not positive divergence (which requires lower price lows with higher momentum lows)

→ vs aggressive: Stop loss at $62.61 assumes frictionless execution; actual gap-down on zola-cel catalyst or Fed surprise risks 14% drawdown to 200 SMA at $57.20, not stated 5.5%

→ vs aggressive: Defensive rotation thesis fails on company-specific risk: low beta protects against market beta but not idiosyncratic pipeline events (zola-cel escalation, Eliquis LOE, forward EPS revision)

Take a modest first tranche at 66.00 to 66.50, size at 1% of book (not 1.5%), keep 50 SMA stop at 62.61, preserve staged build; second tranche at 62.50 to 63.50 on weakness; third tranche only after zola-cel binary resolves or Q3 earnings print

• Fundamental setup is compelling: 10.4x forward earnings, 3.7% yield, Q2 inflection (5.7% revenue growth, 153% EPS jump)
• Technical setup warns of trend exhaustion — prices making higher highs while momentum making lower highs is bearish divergence, not positive divergence
• Tighten entry to 66.00 to 66.50 zone where Bollinger middle and VWMA converge, giving better risk-reward than buying at upper Bollinger Band at $68.09
• Take 1% of book on first tranche (not 1.5%) to respect binary clinical catalyst risk while staying in the trade
• Keep stop at 62.61 (50 SMA support zone) as the line that breaks the structural uptrend thesis
• Preserve second tranche at 62.50 to 63.50 on weakness, third tranche only after zola-cel safety disclosure or Q3 earnings
• Zola-cel risk is real but binary; Oxford Biomedica's 15% drop does not fully price BMY's pipeline and reputational risk
• Aggressive analyst's positive divergence call is incorrect terminology — this is bearish divergence warning of exhaustion
• Conservative analyst over-indexing on tail scenarios; zola-cel pause alone unlikely to move $139B company with $48B revenue by 14%
• Macro factors (hawkish Fed pricing) roughly offset BMY's defensive characteristics; trade works or fails on company-specific execution

→ vs aggressive: Called higher highs with lower momentum 'positive divergence' — this is bearish divergence warning of trend exhaustion, not a reversal setup; acknowledged negative histogram but drew opposite conclusion

→ vs aggressive: Dismissed zola-cel too quickly; Oxford Biomedica's 15% drop reflects contract manufacturer repricing, not full absorption of BMY's safety and pipeline risk

→ vs aggressive: Recommending buying at $66.25 into upper Bollinger Band after six million shares of volume on fresh high following MACD bear cross — paying full price for the move

→ vs conservative: Cash-secured put idea is clever but assumes options capability, margin approval, and mandate flexibility not available to all investors

→ vs conservative: Over-indexing on zola-cel tail risk; treating an autoimmune cell therapy trial pause as material adverse change for $139B company with $48B annual revenue

→ vs conservative: 50 SMA at $62.61 has held every test throughout August; using worst-case gap scenario to argue against normal trade is tail-risk modeling that prevents capital deployment